Joinn Laboratories (China) Co (HKSE:06127) ROCE % : 5.40% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Joinn Laboratories (China) Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Joinn Laboratories (China) Co's annualized ROCE % for the quarter that ended in Sep. 2024 was 5.40%.

Joinn Laboratories (China) Co ROCE % Historical Data

The historical data trend for Joinn Laboratories (China) Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Joinn Laboratories (China) Co ROCE % Chart

Joinn Laboratories (China) Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

25.18

31.42

14.81

14.99

5.91

Joinn Laboratories (China) Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															13.03	5.46	-13.89	5.60	5.40

Joinn Laboratories (China) Co ROCE % Calculation

Joinn Laboratories (China) Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	557.834	/	( ( (11573.871 - 2059.515)	+	(10967.496 - 1604.973) )	/ 2 )
	=	557.834	/	( (9514.356	+	9362.523)	/ 2 )
	=	557.834	/	9438.4395
	=	5.91 %

Joinn Laboratories (China) Co's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	481.32	/	( ( (10400.782 - 1634.403)	+	(10487.665 - 1429.936) )	/ 2 )
	=	481.32	/	( ( 8766.379	+	9057.729 )	/ 2 )
	=	481.32	/	8912.054
	=	5.40 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Joinn Laboratories (China) Co (HKSE:06127) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Joinn Laboratories (China) Co ROCE % Related Terms

Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Joinn Laboratories (China) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Joinn Laboratories (China) Co Ltd (HKSE:06127) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

603127:China

Address

A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176

Website

https://www.joinnlabs.com

Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.

Executives

Yi Fang Da Ji Jin Guan Li You Xian Gong Si	2102 Investment manager
Futu Trustee Limited	2301 Trustee
Ubs Group Ag	2201 Interest of corporation controlled by you
Aggregate Of Abrdn Plc Affiliated Investment Management Entities	2102 Investment manager
Fil Limited	2201 Interest of corporation controlled by you
Pandanus Associates Inc.	2201 Interest of corporation controlled by you
Pandanus Partners L.p.	2201 Interest of corporation controlled by you
Brown Brothers Harriman & Co.	2502 Approved lending agent
Fidelity Funds	2101 Beneficial owner
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Abrdn Asia Focus Plc	2101 Beneficial owner
Morgan Stanley	2201 Interest of corporation controlled by you
The Goldman Sachs Group, Inc.	2201 Interest of corporation controlled by you
Apg Asset Management N.v.	2101 Beneficial owner
Apg Groep N.v.	2101 Beneficial owner

Joinn Laboratories (China) Co Headlines

No Headlines